Shots:
- The US FDA has granted Orphan Drug Designation to Zai Lab’s ZL-1310 for treating small cell lung cancer (SCLC)
- The designation is based on promising P-Ia/Ib trial data of ZL-1310 as monotherapy and with atezolizumab in treatment-experienced ES-SCLC patients, presented at the ENA Symposium 2024
- ZL-1310 is a novel ADC targeting DLL3 expressed in neuroendocrine tumors and a validated SCLC target. It combines a humanized anti-DLL3 antibody with a camptothecin derivative payload using the TMALIN platform to address limitations of first-generation ADCs, such as off-target toxicity
Ref: Zai Lab | Image: Zai Lab
Related News:- argenx and Zai Lab Report the NMPA’s Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
